Cellectis (CLLS) Non-Current Assets (2013 - 2026)
Cellectis (CLLS) posted quarterly Non-Current Assets of $84.6 million for Q1 2026, down 8.26% year-over-year from $92.3 million in Q1 2025, and down 4.34% quarter-over-quarter from $88.5 million in Q4 2025.
Cellectis (CLLS) Non-Current Assets (2013 - 2026) Analysis & Trends
Cellectis' Non-Current Assets history runs 14 years deep, the most recent figure standing at $84.6 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 8.26% year-over-year to $84.6 million; the TTM figure through Mar 2026 stood at $84.6 million (down 8.26% YoY), while the FY2025 annual figure was $88.5 million, down 8.29% from the prior year.
- Non-Current Assets for Q1 2026 stood at $84.6 million, down from $88.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $152.0 million in Q1 2022, with the low at $84.6 million in Q1 2026.
- The 5-year median for Non-Current Assets is $113.2 million (2023), against an average of $112.0 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets declined 25.05% in 2022, then climbed 21.69% in 2025.
- Cellectis' Non-Current Assets stood at $117.4 million in 2022, then decreased by 13.75% to $101.3 million in 2023, then fell by 4.73% to $96.5 million in 2024, then dropped by 8.29% to $88.5 million in 2025, then dropped by 4.34% to $84.6 million in 2026.
- Business Quant data shows CLLS's Non-Current Assets at $84.6 million in Q1 2026, $88.5 million in Q4 2025, and $121.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 84.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.64 Mn |
| Dec 31, 2025 | 88.48 Mn |
| Sep 30, 2025 | 121.85 Mn |
| Jun 30, 2025 | 123.33 Mn |
| Mar 31, 2025 | 92.26 Mn |
| Dec 31, 2024 | 96.48 Mn |
| Sep 30, 2024 | 101.45 Mn |
| Jun 30, 2024 | 101.34 Mn |
| Mar 31, 2024 | 96.39 Mn |
| Dec 31, 2023 | 101.27 Mn |
| Sep 30, 2023 | 113.21 Mn |
| Jun 30, 2023 | 114.39 Mn |
| Mar 31, 2023 | 114.04 Mn |
| Dec 31, 2022 | 117.41 Mn |
| Sep 30, 2022 | 139.31 Mn |
| Jun 30, 2022 | 145.72 Mn |
| Mar 31, 2022 | 152.02 Mn |
| Dec 31, 2021 | 156.65 Mn |
| Sep 30, 2021 | 177.04 Mn |
| Jun 30, 2021 | 177.21 Mn |